I Can Move with Purpose Now! a Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
- Conditions
- Myeloproliferative DisordersLeukemia
- Interventions
- Behavioral: Cardiac Lifestyle Program
- Registration Number
- NCT05842603
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods.
The name of the intervention used in this research study is:
Cardiac Lifestyle Program (a 12-week, tailored nutrition and physical activity program)
- Detailed Description
This is a single-arm, prospective pilot study that will enroll eligible Myeloproliferative Neoplasms (MPN) patients in a 12-week exercise and nutrition-based Cardiac Lifestyle Program (CLP). This research study is a Feasibility Study, which is the first time investigators are examining this exercise program in myeloproliferative disorder patients.
Study procedures include screening for eligibility, an in-clinic visit, questionnaires, program group classes, and blood work.
Participation in this research study is expected to last 12 weeks.
It is expected that about 30 people will take part in this research study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
-≥18 years of age
- Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Must have at least one cardiovascular risk factor including: Body mass index (BMI) >25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study.
-- MF patients with intermediate-2 or high-risk disease by DIPSS
- ECOG performance status >2.
- Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cardiac Lifestyle Program Cardiac Lifestyle Program Participants will complete study procedures as follows: * Baseline in-clinic visit with research team doctor for history and physical and the completion of questionnaires. * 6 virtual group classes alternating with 6 in-person group classes. * Semi-structured exit interview.
- Primary Outcome Measures
Name Time Method Number of Participants that Complete at Least 9 Weeks of the 12 week Program Enrollment to end of the 3 month follow-up of last patient enrolled Feasibility of this pilot trial will be measured by the number of participants that complete at least 9 weeks of the exercise program. This trial will be considered feasible if at least 70% (≥21) of participants complete the program. Completion rates will be measured with a 95% confidence interval for the adherence proportion calculated by exact binomial method.
- Secondary Outcome Measures
Name Time Method Change in FACIT-Fatigue Score from Baseline to Week 12 Baseline and Week 12 (end of program completion) The FACIT-F is a 41-item questionnaire consisting of the FACT-G (28 items), which measures health-related quality of life covering four domains of well-being (physical, social/family, emotional, functional), plus 13 fatigue-specific items. Possible scores range from 0 to 164. Change = Week 12 Score - Baseline Score.
Change in HADS Score from Baseline to Week 12 Baseline and Week 12 (end of program completion) The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report measure of depressive and anxiety symptoms specifically designed for use with medical patients. Possible scores range from 0-42. Change = Week 12 Score - Baseline Score.
Change in IPAQ Short Form Score from Baseline to Week 12 Baseline and Week 12 (end of program completion) The IPAQ Short Form is a 7-item questionnaire that measures the amount and time spent doing various levels of physical activity over the last week. Participant answers are based on number of minutes, hours, or days spent on performing activities of various intensities. Change = Week 12 scores on each item - Baseline scores on each item.
Hematologic Response Rate Baseline and Week 12 (end of program completion) Hematologic response rates are defined by International Working Group (IWG) working criteria including proportion of patients achieving all of the following: platelet count ≤ 400 x 109/L, WBC count \<10 x 109/L, and absence of leukoerythroblastosis, hematocrit \<45%.
Change in MPN SAF-TSS Score from Baseline to Week 12 Baseline and Week 12 (end of program completion) The MPN-SAF TSS is a validated 10-item symptom assessment form that captures the most common symptoms affecting MPN patients, and is considered a standard assessment in clinical trials evaluating interventions in MPN patients. Possible scores range from 0 to 100. Change = Week 12 Score - Baseline Score.
Changes in Healthy Eating Index (HEI) Score from Baseline to Week 12 Baseline and Week 12 (end of program completion) The Automated Self-Administered Dietary Assessment Tool (ASA24), a free web-based 24-hour dietary recall tool developed by the National Cancer Institute. Responses will be used to calculate a Healthy Eating Index (HEI) score, which is based on density values/ratios of intake per total energy. The HEI is a measure of dietary quality that addresses compliance with the 2015 USDA dietary guidelines. Change = Week 12 scores - Baseline scores.
Trial Locations
- Locations (3)
Massachusetts General Hospital Cancer Center
🇺🇸Boston, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States